Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG – Get Free Report) was up 10.5% during mid-day trading on Friday . The company traded as high as $30.63 and last traded at $30.63. Approximately 23,297 shares were traded during trading, a decline of 91% from the average session volume of 253,068 shares. The stock had previously closed at $27.72.
Wall Street Analyst Weigh In
Several analysts have recently commented on the stock. Wall Street Zen raised shares of Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. Zacks Research raised Hemab Therapeutics to a “hold” rating in a research note on Wednesday, May 27th. Jefferies Financial Group initiated coverage on Hemab Therapeutics in a research report on Tuesday, May 26th. They issued a “buy” rating and a $39.00 target price on the stock. HC Wainwright initiated coverage on Hemab Therapeutics in a research note on Wednesday, June 17th. They issued a “buy” rating and a $40.00 price target on the stock. Finally, The Goldman Sachs Group initiated coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They set a “buy” rating and a $36.00 price target for the company. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $41.40.
Check Out Our Latest Analysis on COAG
Hemab Therapeutics Stock Performance
Insider Buying and Selling at Hemab Therapeutics
In other news, major shareholder Ra Capital Management, L.P. acquired 61,523 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The shares were purchased at an average price of $24.98 per share, for a total transaction of $1,536,844.54. Following the acquisition, the insider owned 6,444,637 shares of the company’s stock, valued at $160,987,032.26. This represents a 0.96% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders acquired 2,970,541 shares of company stock valued at $55,459,603 over the last ninety days.
About Hemab Therapeutics
Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.
Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.
Featured Articles
- Five stocks we like better than Hemab Therapeutics
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Receive News & Ratings for Hemab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
